Amundi’s Xenon Pharmaceuticals XENE Stock Holding History

Amundi’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$647K	Sell	10,719 -7,294	-40%	-$405K	﹤0.01%	1556
2026 Q1	$1.05M	Buy	18,013 +13,404	+291%	+$618K	﹤0.01%	1274
2025 Q4	$207K	Buy	+4,609	New	+$194K	﹤0.01%	1757
2025 Q2	–	Sell	-114	Closed	-$3.5K	–	2204
2025 Q1	$3.5K	Buy	114 +25	+28%	+$949	﹤0.01%	1934
2024 Q4	$3.52K	Buy	+89	New	+$3.68K	﹤0.01%	1957
2022 Q4	–	Sell	-3,581	Closed	-$133K	–	1989
2022 Q3	$133K	Hold	3,581	–	–	﹤0.01%	1515
2022 Q2	$115K	Sell	3,581 -745	-17%	-$22.5K	﹤0.01%	1425
2022 Q1	$148K	Sell	4,326 -202	-4%	-$6.05K	﹤0.01%	1420
2021 Q4	$132K	Buy	+4,528	New	+$135K	﹤0.01%	1536

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Amundi's XENE Position: Q2 2026 in Review

Amundi reduced its Xenon Pharmaceuticals (XENE) stake by 40% in Q2 2026, selling an estimated $405K and leaving 10,719 shares worth $647K. The position accounts for ﹤0.01% of the portfolio, ranked #1556.

Amundi first reported a position in XENE in Q4 2021 and has held it in 9 quarters since. The position peaked at $1.05M in Q1 2026. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Amundi held 10,719 shares of Xenon Pharmaceuticals worth $647K as of Q2 2026.
Amundi sold 7,294 Xenon Pharmaceuticals shares in Q2 2026, an estimated $405K.
Xenon Pharmaceuticals made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1556 holding.
Amundi first reported a position in Xenon Pharmaceuticals in Q4 2021 and has held it in 9 quarters since.
Amundi's Xenon Pharmaceuticals position peaked at $1.05M in Q1 2026.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.